Novartis welcomes the Biotech Act as a concrete step towards strengthening Europes life sciences ecosystem. By promoting simplification, regulatory coherence, reduced administrative burden and a stronger IP framework, the Act can support innovation and enhance Europes attractiveness for research, development, manufacturing and investment. To maximise its impact, Novartis highlights three priorities. 1.
NOV
Novartis
Company · Belgium · EU Transparency Register 91269481588-28
3
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #303 by legislative files engaged — a count of participation, not a measure of influence.
3.2
declared lobbying FTE
self-declared
€2.5M+
declared costs / yr (floor)
6
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Business Europe Membership
- Critical Medicines Alliance
- ECPA
- EFPIA - Pillar 3 IMI
- EFPIA (Pillar 1+2)
- EFPIA: Pillar 3 ICH
- EFPIA Country engagement
- EFPIA Campaign mode
- EFPIA - Contribution to Fairer pharmaceutical spending & improved industrial ecosystem in Europe 'advocacy 1 communic…
- Eucope (Membership)
- Eucope Membership - Support to the incentive Steering Group (ISG)
- Eucope Membership (OLU WG)
- and 19 more
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Registered as
- Novartis International AG
- Head office
- Basel, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Novartis in PolicySpeak: request access →
Work at Novartis? so we know who speaks for it.
Their record over time
Novartis filed 3 positions between 24 Apr 2026 and 5 Aug 2026, across 3 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
Novartis welcomes the European Commissions initiative to strengthen early detection and screening of cardiovascular diseases (CVDs) as a core pillar of the EU Safe Hearts Plan. CVDs remain the leading cause of mortality and morbidity in Europe, requiring more systematic and appropriate CV risk stratification to reduce avoidable disease, health inequalities and long-term pressure on health systems.
Lifesaving nuclear medicine should be regulated with the same rigor as other nuclear activities, but not in the same way. For innovative radiopharmaceuticals, high safety standards can be maintained while reducing unnecessary system burden by applying a pragmatic, risk and exposure-based approach to radioactive waste management, grounded in low medical doses, low volumes, safe handling conditions, and real-world…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- MedTech Europe · 2 files in common
- EFPIA · 2 files in common
- EURAMET e.V. · 2 files in common
- Deutsche Sozialversicherung Europavertretung (DSV) · 2 files in common
Showing 5 of 21.
Is this your organization?
Everything on this page comes from Novartis’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.